215 related articles for article (PubMed ID: 27067336)
1. Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis.
Alsaad N; Dijkstra JA; Akkerman OW; de Lange WC; van Soolingen D; Kosterink JG; van der Werf TS; Alffenaar JW
Antimicrob Agents Chemother; 2016 Jul; 60(7):3942-7. PubMed ID: 27067336
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis.
Alsaad N; van Altena R; Pranger AD; van Soolingen D; de Lange WC; van der Werf TS; Kosterink JG; Alffenaar JW
Eur Respir J; 2013 Aug; 42(2):504-12. PubMed ID: 23100498
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients.
Van't Boveneind-Vrubleuskaya N; Seuruk T; van Hateren K; van der Laan T; Kosterink JGW; van der Werf TS; van Soolingen D; van den Hof S; Skrahina A; Alffenaar JC
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507117
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic Modeling, Simulation, and Development of a Limited Sampling Strategy of Cycloserine in Patients with Multidrug-/Extensively Drug-Resistant Tuberculosis.
van der Galiën R; Boveneind-Vrubleuskaya NV; Peloquin C; Skrahina A; Touw DJ; Alffenaar JC
Clin Pharmacokinet; 2020 Jul; 59(7):899-910. PubMed ID: 31981103
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB.
Ghimire S; Van't Boveneind-Vrubleuskaya N; Akkerman OW; de Lange WC; van Soolingen D; Kosterink JG; van der Werf TS; Wilffert B; Touw DJ; Alffenaar JW
J Antimicrob Chemother; 2016 Oct; 71(10):2691-703. PubMed ID: 27231277
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetics of Linezolid in Tuberculosis Patients: Dosing Regimen Simulation and Target Attainment Analysis.
Alghamdi WA; Al-Shaer MH; An G; Alsultan A; Kipiani M; Barbakadze K; Mikiashvili L; Ashkin D; Griffith DE; Cegielski JP; Kempker RR; Peloquin CA
Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32778547
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.
de Kock L; Sy SK; Rosenkranz B; Diacon AH; Prescott K; Hernandez KR; Yu M; Derendorf H; Donald PR
Antimicrob Agents Chemother; 2014 Oct; 58(10):6242-50. PubMed ID: 25114132
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis.
van Rijn SP; van Altena R; Akkerman OW; van Soolingen D; van der Laan T; de Lange WC; Kosterink JG; van der Werf TS; Alffenaar JW
Eur Respir J; 2016 Apr; 47(4):1229-34. PubMed ID: 26743484
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.
van Rijn SP; Zuur MA; van Altena R; Akkerman OW; Proost JH; de Lange WC; Kerstjens HA; Touw DJ; van der Werf TS; Kosterink JG; Alffenaar JW
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137814
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis Patients.
Zuur MA; Ghimire S; Bolhuis MS; Wessels AMA; van Altena R; de Lange WCM; Kosterink JGW; Touw DJ; van der Werf TS; Akkerman OW; Alffenaar JWC
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29439978
[TBL] [Abstract][Full Text] [Related]
11. Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis.
Alghamdi WA; Alsultan A; Al-Shaer MH; An G; Ahmed S; Alkabab Y; Banu S; Barbakadze K; Houpt E; Kipiani M; Mikiashvili L; Schmidt S; Heysell SK; Kempker RR; Cegielski JP; Peloquin CA
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858211
[TBL] [Abstract][Full Text] [Related]
12. Ethionamide Population Pharmacokinetic Model and Target Attainment in Multidrug-Resistant Tuberculosis.
Al-Shaer MH; Märtson AG; Alghamdi WA; Alsultan A; An G; Ahmed S; Alkabab Y; Banu S; Houpt ER; Ashkin D; Griffith DE; Cegielski JP; Heysell SK; Peloquin CA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631828
[TBL] [Abstract][Full Text] [Related]
13. Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis.
Alsaad N; Wilffert B; van Altena R; de Lange WC; van der Werf TS; Kosterink JG; Alffenaar JW
Eur Respir J; 2014 Mar; 43(3):884-97. PubMed ID: 23988774
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics and Dose Evaluation of Cycloserine among Patients with Multidrug-Resistant Tuberculosis under Standardized Treatment Regimens.
Zhu Y; Zhu L; Davies Forsman L; Paues J; Werngren J; Niward K; Schön T; Bruchfeld J; Xiong H; Alffenaar JW; Hu Y
Antimicrob Agents Chemother; 2023 May; 67(5):e0170022. PubMed ID: 37097151
[TBL] [Abstract][Full Text] [Related]
15. Intra- and extracellular activities of trimethoprim-sulfamethoxazole against susceptible and multidrug-resistant Mycobacterium tuberculosis.
Davies Forsman L; Schön T; Simonsson US; Bruchfeld J; Larsson M; Juréen P; Sturegård E; Giske CG; Ängeby K
Antimicrob Agents Chemother; 2014 Dec; 58(12):7557-9. PubMed ID: 25246405
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis.
Chang MJ; Jin B; Chae JW; Yun HY; Kim ES; Lee YJ; Cho YJ; Yoon HI; Lee CT; Park KU; Song J; Lee JH; Park JS
Int J Antimicrob Agents; 2017 Jun; 49(6):677-687. PubMed ID: 28408267
[TBL] [Abstract][Full Text] [Related]
17. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
Verbeeck RK; Günther G; Kibuule D; Hunter C; Rennie TW
Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients.
Tietjen AK; Kroemer N; Cattaneo D; Baldelli S; Wicha SG
Br J Clin Pharmacol; 2022 Feb; 88(4):1835-1844. PubMed ID: 34622478
[TBL] [Abstract][Full Text] [Related]
19. Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis.
Srivastava S; Modongo C; Siyambalapitiyage Dona CW; Pasipanodya JG; Deshpande D; Gumbo T
Antimicrob Agents Chemother; 2016 Oct; 60(10):5922-7. PubMed ID: 27458215
[TBL] [Abstract][Full Text] [Related]
20. Sulfamethoxazole susceptibility of Mycobacterium tuberculosis isolates from HIV-infected Ugandan adults with tuberculosis taking trimethoprim-sulfamethoxazole prophylaxis.
Ogwang S; Good CE; Okware B; Nsereko M; Jacobs MR; Boom WH; Bark CM
Antimicrob Agents Chemother; 2015 Sep; 59(9):5844-6. PubMed ID: 26169400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
